SynthesisJournal of gastrointestinal cancer2026
Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte Index in Hepatobiliary and Pancreatic Cancers: A Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe C-reactive protein-albumin-lymphocyte (CALLY) index integrates systemic inflammation, nutritional status, and immune competence, but evidence in hepatobiliary and pancreatic (HBP) malignancies remains uncertain. We evaluated its association with survival outcomes.
methodsA systematic search of PubMed, Embase, Scopus, and Web of Science was performed from inception to 9 September 2026. Observational studies involving adults with hepatobiliary and pancreatic malignancies were eligible if they evaluated pretreatment CALLY and reported HRs for survival outcomes. Random-effects were used to pool HRs for overall survival (OS) and recurrence-free/disease-free survival (RFS/DFS). Risk of bias was assessed using the Newcastle-Ottawa Scale, and certainty of evidence was evaluated using GRADE.
resultsSixteen studies (17 cohorts; 3,833 participants) were included. High CALLY was associated with better OS across 17 cohorts (HR 0.50, 95% CI 0.44-0.58; I²=35.3%) and better RFS/DFS across eight cohorts (HR 0.60, 95% CI 0.49-0.73; I²=55.0%). Cancer-specific OS estimates favored high CALLY in hepatocellular carcinoma (HR 0.58), cholangiocarcinoma (CCA)/biliary tract cancer (HR 0.47), and pancreatic cancer (HR 0.46). Exploratory anatomical stratification of CCA reduced heterogeneity from 56.5% overall to 11.0% in intrahepatic CCA and 0% in mixed CCA/biliary cohorts. Leave-one-out analyses identified no influential cohort. Funnel-plot asymmetry suggested small-study effects for OS. Evidence certainty was moderate for both outcomes.
conclusionHigh pretreatment CALLY was associated with favorable survival across HBP malignancies. Predominantly retrospective evidence, heterogeneous clinical settings, variable cutoffs, and possible small-study effects preclude routine clinical use. Prospective multicenter validation using standardized thresholds is required.
Indexed as
Identifiers
42782412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.